bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Authors: Orzan Francesca , De Bacco Francesca , Lazzarini Elisabetta , Crisafulli Giovanni , Gasparini Alessandra , Dipasquale Angelo , Barault Ludovic , Macagno Marco , Persico Pasquale , Pessina Federico , Bono Beatrice , Giordano Laura , Zeppa Pietro , Melcarne Antonio , Cassoni Paola , Garbossa Diego , Santoro Armando , Comoglio Paolo M. , Indraccolo Stefano , Simonelli Matteo , Boccaccio Carla
Published: April 2023

AbstractPurpose:
Current glioma diagnostic guidelines call for molecular profiling to stratify patients into prognostic and treatment subgroups. In case the tumor tissue is inaccessible, cerebrospinal fluid (CSF) has been proposed as a reliable tumor DNA source for liquid biopsy. We prospectively investigated the use of CSF for molecular characterization of newly diagnosed gliomas.
Experimental Design:
We recruited two cohorts of newly diagnosed patients with glioma, one (n = 45) providing CSF collected in proximity of the tumor, the other (n = 39) CSF collected by lumbar puncture (LP). Both cohorts provided tumor tissues by surgery concomitant with CSF sampling. DNA samples retrieved from CSF and matched tumors were systematically characterized and compared by comprehensive (NGS, next-generation sequencing) or targeted (ddPCR, droplet digital PCR) methodologies. Conventional and molecular diagnosis outcomes were compared.
Results:
We report that tumor DNA is abundant in CSF close to the tumor, but scanty and mostly below NGS sensitivity threshold in CSF from LP. Indeed, tumor DNA is mostly released by cells invading liquoral spaces, generating a gradient that attenuates by departing from the tumor. Nevertheless, in >60% of LP CSF samples, tumor DNA is sufficient to assess a selected panel of genetic alterations (IDH and TERT promoter mutations, EGFR amplification, CDKN2A/B deletion: ITEC protocol) and MGMT methylation that, combined with imaging, enable tissue-agnostic identification of main glioma molecular subtypes.
Conclusions:
This study shows potentialities and limitations of CSF liquid biopsy in achieving molecular characterization of gliomas at first clinical presentation and proposes a protocol to maximize diagnostic information retrievable from CSF DNA.
Supplementary Figure 1 from Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma
Authors: Cloninger Cheri , Bernath Andrew , Bashir Tariq , Holmes Brent , Artinian Nicholas , Ruegg Teresa , Anderson Lauren , Masri Janine , Lichtenstein Alan , Gera Joseph
Published: April 2023

PDF file - 197K
Supplementary Figure 2 from Enhanced Antitumor Effects by Chemical Modified IGb3 Analogues
Authors: Zhou Zhixia , Zhang Cai , Xia Chengfeng , Chen Wenlan , Zhu Huawei , Shang Pingping , Ma Fang , Wang Peng George , Zhang Jian , Xu Wenfang , Tian Zhigang
Published: April 2023

Supplementary Figure 2 from Enhanced Antitumor Effects by Chemical Modified IGb3 Analogues
Supplementary Table 4 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Authors: Lund Per , Kotova Irina , Kedinger Valérie , Khanwalkar Harshal , Voltz Emilie , Hahn William C. , Gronemeyer Hinrich
Published: April 2023

Supplementary Table 4 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Supplementary Figures 1-5 from Long Pentraxin-3 Inhibits FGF8b-Dependent Angiogenesis and Growth of Steroid Hormone–Regulated Tumors
Authors: Leali Daria , Alessi Patrizia , Coltrini Daniela , Ronca Roberto , Corsini Michela , Nardo Giorgia , Indraccolo Stefano , Presta Marco
Published: April 2023

PDF file - 142K
Supplementary Figures 1-3, Tables 1-6 from Prioritizing Candidate Disease miRNAs by Topological Features in the miRNA Target–Dysregulated Network: Case Study of Prostate Cancer
Authors: Xu Juan , Li Chuan-Xing , Lv Jun-Ying , Li Yong-Sheng , Xiao Yun , Shao Ting-Ting , Huo Xiao , Li Xiang , Zou Yan , Han Qing-Lian , Li Xia , Wang Li-Hua , Ren Huan
Published: April 2023

PDF file - 287K
Supplementary Figures 1-2 from Neutralizing Monoclonal Antibody to Periostin Inhibits Ovarian Tumor Growth and Metastasis
Authors: Zhu Min , Saxton Romaine E. , Ramos Lillian , Chang David D. , Karlan Beth Y. , Gasson Judith C. , Slamon Dennis J.
Published: April 2023

Supplementary Figures 1-2 from Neutralizing Monoclonal Antibody to Periostin Inhibits Ovarian Tumor Growth and Metastasis
Supplementary Figure Legend from Cell Intrinsic Role of COX-2 in Pancreatic Cancer Development
Authors: Hill Reginald , Li Yunfeng , Tran Linh M. , Dry Sarah , Calvopina Joseph Hargan , Garcia Alejandro , Kim Christine , Wang Ying , Donahue Timothy R. , Herschman Harvey R. , Wu Hong
Published: April 2023

PDF file, 81K.
Supplementary Figure 2 from Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
Authors: Piguet Anne-Christine , Saar Bettina , Hlushchuk Ruslan , St-Pierre Marie V. , McSheehy Paul M.J. , Radojevic Vesna , Afthinos Maresa , Terracciano Luigi , Djonov Valentin , Dufour Jean-François
Published: April 2023

Supplementary Figure 2 from Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
Supplementary Figure 3 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Authors: Caldon C. Elizabeth , Sergio C. Marcelo , Kang Jian , Muthukaruppan Anita , Boersma Marijke N. , Stone Andrew , Barraclough Jane , Lee Christine S. , Black Michael A. , Miller Lance D. , Gee Julia M. , Nicholson Rob I. , Sutherland Robert L. , Print Cristin G. , Musgrove Elizabeth A.
Published: April 2023

PDF file, 41KB, Supplementary Figure 3: Effect of overexpression of cyclins E1 and E2 on antiestrogen-induced growth arrest. T-47D cells overexpressing cyclin E1, cyclin E2 or vector control were treated with fulvestrant or vehicle. Densitometry of Western blots of cell lysates collected after 24h (A) or 48h (B) fulvestrant treatment. Loading was corrected using β-actin levels. Data represent mean � SEM of quadruplicate experiments.
Supplementary Figure 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Authors: Caldon C. Elizabeth , Sergio C. Marcelo , Kang Jian , Muthukaruppan Anita , Boersma Marijke N. , Stone Andrew , Barraclough Jane , Lee Christine S. , Black Michael A. , Miller Lance D. , Gee Julia M. , Nicholson Rob I. , Sutherland Robert L. , Print Cristin G. , Musgrove Elizabeth A.
Published: April 2023

PDF file, 78KB, Supplementary Figure 2: Deregulation of cyclin E in tamoxifen-resistant cells. MCF-7C and TAMR cells were treated with vehicle, OH-Tam (100 nM) or fulvestrant (10 nM). A: S phase percentage derived from flow cytometry of propidium iodide-stained cells. B: Densitometry of Western blots using GAPDH as a loading control. Data represent the mean � range of duplicate experiments.
Supplementary Figure Legends 1-2 from Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma
Authors: McFarland Braden C. , Ma Jing-Yuan , Langford Catherine P. , Gillespie G. Yancey , Yu Hao , Zheng Ying , Nozell Susan E. , Huszar Dennis , Benveniste Etty N.
Published: April 2023

PDF file - 72K
Supplementary Figure 2 from Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma
Authors: McFarland Braden C. , Ma Jing-Yuan , Langford Catherine P. , Gillespie G. Yancey , Yu Hao , Zheng Ying , Nozell Susan E. , Huszar Dennis , Benveniste Etty N.
Published: April 2023

PDF file - 170K
Supplementary Methods, Tables 1-2, Figures 1-3 from Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
Authors: Van Maerken Tom , Rihani Ali , Dreidax Daniel , De Clercq Sarah , Yigit Nurten , Marine Jean-Christophe , Westermann Frank , De Paepe Anne , Vandesompele Jo , Speleman Frank
Published: April 2023

Supplementary Methods, Tables 1-2, Figures 1-3 from Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
Supplementary Figures 1-2 from Genomic Profiling in CEPH Cell Lines Distinguishes between the Camptothecins and Indenoisoquinolines
Authors: Watson Venita Gresham , Hardison Nicholas E. , Harris Tyndall , Motsinger-Reif Alison , McLeod Howard L.
Published: April 2023

PDF file - 354K
Supplementary Figure Legend from Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Authors: Yi Ping , Higa Arisa , Taouji Said , Bexiga Mariana G. , Marza Esther , Arma Daniela , Castain Claire , Le Bail Brigitte , Simpson Jeremy C. , Rosenbaum Jean , Balabaud Charles , Bioulac-Sage Paulette , Blanc Jean-Frédéric , Chevet Eric
Published: April 2023

PDF file - 71K
Supplementary Figure 2 from Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Authors: Yi Ping , Higa Arisa , Taouji Said , Bexiga Mariana G. , Marza Esther , Arma Daniela , Castain Claire , Le Bail Brigitte , Simpson Jeremy C. , Rosenbaum Jean , Balabaud Charles , Bioulac-Sage Paulette , Blanc Jean-Frédéric , Chevet Eric
Published: April 2023

PDF file - 510K, Figure S2. (A) HepG2 cells were either not treated or treated with 10 μM Sorafenib for 4 h, after which they were either fixed or Sorafenib removed from cells and fresh medium added for a further 2 h. Cells were then stained with anti Giantin (green). Scale bars correspond to 25 μm. (B) The number of cells containing fragmented Golgi complex was quantified. Between 200 and 400 cells were analyzed for each condition and results are represented as the means � SD. Student's t-test *: p < 0.03, compared to control, #: p < 0.03 HepG2 mock transfected compared to IRE1-DN transfected cells.
Supplementary Figure 1 from Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Authors: Yi Ping , Higa Arisa , Taouji Said , Bexiga Mariana G. , Marza Esther , Arma Daniela , Castain Claire , Le Bail Brigitte , Simpson Jeremy C. , Rosenbaum Jean , Balabaud Charles , Bioulac-Sage Paulette , Blanc Jean-Frédéric , Chevet Eric
Published: April 2023

PDF file - 877K, Figure S1. (A) Quantification of Xbp1 mRNA splicing shown in Figure 2A. (B) Wild-type HepG2 cells were either not treated or treated with 10 μM Sorafenib for 2 h followed by staining for giantin, a Golgi complex marker, α-tubulin, as a marker for the microtubules and Hoechst 33342 as a nuclear marker. (C) Cells treated as above were immunostained against giantin and phalloidin was used to stain the actin cytoskeleton. Images were acquired by wide-field fluorescence microscopy. Scale bars correspond to 25 μm.
Supplementary Table 1 from DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma
Authors: Xu Xiao , Liu Rui-Fang , Zhang Xin , Huang Li-Yu , Chen Fei , Fei Qian-Lan , Han Ze-Guang
Published: April 2023

PDF file - 64K
Supplementary Figure 2 from Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer
Authors: Wilson Peter M. , LaBonte Melissa J. , Lenz Heinz-Josef , Mack Philip C. , Ladner Robert D.
Published: April 2023

PDF file - 193K
Supplementary Figure 3 from DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma
Authors: Xu Xiao , Liu Rui-Fang , Zhang Xin , Huang Li-Yu , Chen Fei , Fei Qian-Lan , Han Ze-Guang
Published: April 2023

PDF file - 129K
Supplementary Figures 1-2 from PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Authors: Janku Filip , Tsimberidou Apostolia M. , Garrido-Laguna Ignacio , Wang Xuemei , Luthra Rajyalakshmi , Hong David S. , Naing Aung , Falchook Gerald S. , Moroney John W. , Piha-Paul Sarina A. , Wheler Jennifer J. , Moulder Stacy L. , Fu Siqing , Kurzrock Razelle
Published: April 2023

Supplementary Figures 1-2 from PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Supplementary Figure Legend from Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer
Authors: Giordano Antonio , Gao Hui , Anfossi Simone , Cohen Evan , Mego Michal , Lee Bang-Ning , Tin Sanda , De Laurentiis Michele , Parker Charla A. , Alvarez Ricardo H. , Valero Vicente , Ueno Naoto T. , De Placido Sabino , Mani Sendurai A. , Esteva Francisco J. , Cristofanilli Massimo , Reuben James M.
Published: April 2023

PDF file - 86K
Supplementary Table 1 from Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA
Authors: Jones Richard J. , Bjorklund Chad C. , Baladandayuthapani Veerabhadran , Kuhn Deborah J. , Orlowski Robert Z.
Published: April 2023

PDF file, 65K, IC50 values of MI63R and NutlinR cell lines to HDM-2 Inhibitors.
Supplementary Figure Legend from Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family
Authors: Brave Sandra R. , Ratcliffe Kirsty , Wilson Zena , James Neil H. , Ashton Sue , Wainwright Anna , Kendrew Jane , Dudley Philippa , Broadbent Nicola , Sproat Graham , Taylor Sian , Barnes Claire , Silva Jeffrey C. , Farnsworth Charles L. , Hennequin Laurent , Ogilvie Donald J. , Jürgensmeier Juliane M. , Shibuya Masabumi , Wedge Stephen R. , Barry Simon T.
Published: April 2023

Supplementary Figure Legend from Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family
Supplementary Figure 1 from Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family
Authors: Brave Sandra R. , Ratcliffe Kirsty , Wilson Zena , James Neil H. , Ashton Sue , Wainwright Anna , Kendrew Jane , Dudley Philippa , Broadbent Nicola , Sproat Graham , Taylor Sian , Barnes Claire , Silva Jeffrey C. , Farnsworth Charles L. , Hennequin Laurent , Ogilvie Donald J. , Jürgensmeier Juliane M. , Shibuya Masabumi , Wedge Stephen R. , Barry Simon T.
Published: April 2023

Supplementary Figure 1 from Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family
Supplementary Figure Legend from Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity
Authors: Kuramoto Takuya , Goto Hisatsugu , Mitsuhashi Atsushi , Tabata Sho , Ogawa Hirohisa , Uehara Hisanori , Saijo Atsuro , Kakiuchi Soji , Maekawa Yoichi , Yasutomo Koji , Hanibuchi Masaki , Akiyama Shin-ichi , Sone Saburo , Nishioka Yasuhiko
Published: April 2023

PDF file - 83K
Supplementary Figure 2 from Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity
Authors: Kuramoto Takuya , Goto Hisatsugu , Mitsuhashi Atsushi , Tabata Sho , Ogawa Hirohisa , Uehara Hisanori , Saijo Atsuro , Kakiuchi Soji , Maekawa Yoichi , Yasutomo Koji , Hanibuchi Masaki , Akiyama Shin-ichi , Sone Saburo , Nishioka Yasuhiko
Published: April 2023

PDF file - 50K, The effect of recombinant Dll4-Fc on the NF-κB activity of SBC-3-vector cells
Supplementary Figure 1 from Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity
Authors: Kuramoto Takuya , Goto Hisatsugu , Mitsuhashi Atsushi , Tabata Sho , Ogawa Hirohisa , Uehara Hisanori , Saijo Atsuro , Kakiuchi Soji , Maekawa Yoichi , Yasutomo Koji , Hanibuchi Masaki , Akiyama Shin-ichi , Sone Saburo , Nishioka Yasuhiko
Published: April 2023

PDF file - 116K, Extracellular domain of murine Dll4-fused to Fc (Dll4-Fc) expressed in H1048 and SBC-5 cells
Supplementary Figure 3 from Human Monoclonal Antibody Fragments Binding to Insulin-like Growth Factors I and II with Picomolar Affinity
Authors: Zhao Qi , Feng Yang , Zhu Zhongyu , Dimitrov Dimiter S.
Published: April 2023

PDF file - 55K
Supplementary Figure Legends 1-5 from In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer
Authors: Kinross Kathryn M. , Brown Daniel V. , Kleinschmidt Margarete , Jackson Susan , Christensen James , Cullinane Carleen , Hicks Rodney J. , Johnstone Ricky W. , McArthur Grant A.
Published: April 2023

Supplementary Figure Legends 1-5 from In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer
Supplementary Table 1 from Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells
Authors: Tai Sheng , Sun Yin , Liu Nan , Ding Boxiao , Hsia Elaine , Bhuta Sunita , Thor Ryan K. , Damoiseaux Robert , Liang Chaozhao , Huang Jiaoti
Published: April 2023

PDF File, 1123KB, The combination index (CI) values of each mixture treatment calculated with CalcuSyn software for PC3 (A) and C4-2 (B) cells.
Supplementary Table 1 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Authors: Hegi Monika E. , Diserens Annie-Claire , Bady Pierre , Kamoshima Yuta , Kouwenhoven Mathilde C. M. , Delorenzi Mauro , Lambiv Wanyu L. , Hamou Marie-France , Matter Matthias S. , Koch Arend , Heppner Frank L. , Yonekawa Yasuhiro , Merlo Adrian , Frei Karl , Mariani Luigi , Hofer Silvia
Published: April 2023

Supplementary Table 1 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Supplementary Figure 2 from Pancratistatin Selectively Targets Cancer Cell Mitochondria and Reduces Growth of Human Colon Tumor Xenografts
Authors: Griffin Carly , Karnik Aditya , McNulty James , Pandey Siyaram
Published: April 2023

Supplementary Figure 2 from Pancratistatin Selectively Targets Cancer Cell Mitochondria and Reduces Growth of Human Colon Tumor Xenografts
Supplementary Table 1 from Cancer Cells Cyclically Lose and Regain Drug-Resistant Highly Tumorigenic Features Characteristic of a Cancer Stem-like Phenotype
Authors: He Kaijie , Xu Tong , Goldkorn Amir
Published: April 2023

Supplementary Table 1 from Cancer Cells Cyclically Lose and Regain Drug-Resistant Highly Tumorigenic Features Characteristic of a Cancer Stem-like Phenotype
Supplementary Figure 3 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Authors: Hegi Monika E. , Diserens Annie-Claire , Bady Pierre , Kamoshima Yuta , Kouwenhoven Mathilde C. M. , Delorenzi Mauro , Lambiv Wanyu L. , Hamou Marie-France , Matter Matthias S. , Koch Arend , Heppner Frank L. , Yonekawa Yasuhiro , Merlo Adrian , Frei Karl , Mariani Luigi , Hofer Silvia
Published: April 2023

Supplementary Figure 3 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Supplementary Figures 1-7, Methods from ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
Authors: Hatzivassiliou Georgia , Liu Bonnie , O'Brien Carol , Spoerke Jill M. , Hoeflich Klaus P. , Haverty Peter M. , Soriano Robert , Forrest William F. , Heldens Sherry , Chen Huifen , Toy Karen , Ha Connie , Zhou Wei , Song Kyung , Friedman Lori S. , Amler Lukas C. , Hampton Garret M. , Moffat John , Belvin Marcia , Lackner Mark R.
Published: April 2023

PDF file - 451K
Supplementary Figure 7 from Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9
Authors: Dolloff Nathan G. , Allen Joshua E. , Dicker David T. , Aqui Nicole , Vogl Dan , Malysz Jozef , Talamo Giampaolo , El-Deiry Wafik S.
Published: April 2023

PDF file, 124K, Comparison of MM oncoprotein and housekeeper protein half-lives.
Supplementary Figure 1 from BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
Authors: Awasthi Niranjan , Zhang Changhua , Ruan Winston , Schwarz Margaret A. , Schwarz Roderich E.
Published: April 2023

PDF file - 43K, Effects of gemcitabine and BMS-754807 therapy on mouse body weight. Nude mice were subcutaneously injected with AsPC-1 cell (0.75 x 106). Fourteen days after tumor cell injection, therapy was started with gemcitabine and BMS-754807 for 2 weeks. Mouse body weight was measured twice a week. Data are representative of mean values � standard deviation from 6-8 mice per group.
Supplementary Figure 2 from Genetic Variation That Predicts Platinum Sensitivity Reveals the Role of miR-193b* in Chemotherapeutic Susceptibility
Authors: Ziliak Dana , Gamazon Eric R. , LaCroix Bonnie , Kyung Im Hae , Wen Yujia , Huang Rong Stephanie
Published: April 2023

PDF file, 90K, Graphical illustration of the relationships among the SNP rs1649942, 2 platinum-associated miRNAs and 5 platinum-associated target genes.
Supplementary Materials and Methods; Supplmentary Tables 1-5; Supplementary Figures 1-5 from APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fcγ Receptors
Authors: Gieffers Christian , Kluge Michael , Merz Christian , Sykora Jaromir , Thiemann Meinolf , Schaal René , Fischer Carmen , Branschädel Marcus , Abhari Behnaz Ahangarian , Hohenberger Peter , Fulda Simone , Fricke Harald , Hill Oliver
Published: April 2023

PDF - 602 KB, Supplementary Investigations: Methods and Result. Table S1: Overview on TRAIL receptor agonists used. Table S2: Binding of APG350 and Apo2L/TRAIL to TRAIL receptors. Table S3: TRAIL receptor surface expression as determined by flow cytometry. Table S4: Mean tumor volumes (mm?) and SEM values of Figure 4A and Figure S5. Table S5: Mean tumor volumes (mm?) and SEM values of Figure 4B and Figure 5B. Figure S1: Design of the single chain TRAIL receptor binding domain. Figure S2: Fractionation of ?bulk? anti-DR5 antibody by SEC. Figure S3: Cytotoxicity of scTRAIL-RBD and APG350 on Colo205 cells with and without cross-linking (MTS-assay). Figure S4: Immunoprecipitation (IP) of DISC from T98G cells after treatment with different TRAIL-R agonists. Figure S5: Effect of APG350 on large Colo205 cell-derived xenograft tumors.
Supplementary Figure 7 from Activity of a Py–Im Polyamide Targeted to the Estrogen Response Element
Authors: Nickols Nicholas G. , Szablowski Jerzy O. , Hargrove Amanda E. , Li Benjamin C. , Raskatov Jevgenij A. , Dervan Peter B.
Published: April 2023

PDF File - 776K, Confocal microscopy of live, cultured T47D-KBLUC cells.
Supplementary Figure Legend from O(6)-Methylguanine-DNA Methyltransferase Is a Novel Negative Effector of Invasion in Glioblastoma Multiforme
Authors: Chahal Manik , Abdulkarim Bassam , Xu Yaoxian , Guiot Marie-Christine , Easaw Jacob C. , Stifani Nicolas , Sabri Siham
Published: April 2023

PDF file - 94K
Supplementary Figure 5 from Activity of a Py–Im Polyamide Targeted to the Estrogen Response Element
Authors: Nickols Nicholas G. , Szablowski Jerzy O. , Hargrove Amanda E. , Li Benjamin C. , Raskatov Jevgenij A. , Dervan Peter B.
Published: April 2023

PDF File - 31K, Relative mRNA of E2 induced tff1 in the presence of 1 at 2 �M.
Supplementary Figure 2 from Activity of a Py–Im Polyamide Targeted to the Estrogen Response Element
Authors: Nickols Nicholas G. , Szablowski Jerzy O. , Hargrove Amanda E. , Li Benjamin C. , Raskatov Jevgenij A. , Dervan Peter B.
Published: April 2023

PDF File - 107K, Representative data from luciferase and cytotoxicity (wst-1) assays for compounds 1-4.
Supplementary Methods and Figure Legend from Breakdown of the FLT3-ITD/STAT5 Axis and Synergistic Apoptosis Induction by the Histone Deacetylase Inhibitor Panobinostat and FLT3-Specific Inhibitors
Authors: Pietschmann Kristin , Bolck Hella Anna , Buchwald Marc , Spielberg Steffi , Polzer Harald , Spiekermann Karsten , Bug Gesine , Heinzel Thorsten , Böhmer Frank-Dietmar , Krämer Oliver H.
Published: April 2023

PDF file, 69K.
Supplementary Figure 1 from Activity of a Py–Im Polyamide Targeted to the Estrogen Response Element
Authors: Nickols Nicholas G. , Szablowski Jerzy O. , Hargrove Amanda E. , Li Benjamin C. , Raskatov Jevgenij A. , Dervan Peter B.
Published: April 2023

PDF File - 43K, Structures of Py-Im polyamides used in the study.
Supplementary Figure Legend from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts
Authors: Gerber David E. , Gupta Puja , Dellinger Michael T. , Toombs Jason E. , Peyton Michael , Duignan Inga , Malaby Jennifer , Bailey Timothy , Burns Colleen , Brekken Rolf A. , Loizos Nick
Published: April 2023

PDF file, 46K.
Supplementary Methods and Figure Legends from Dibenzophenanthridines as Inhibitors of Glutaminase C and Cancer Cell Proliferation
Authors: Katt William P. , Ramachandran Sekar , Erickson Jon W. , Cerione Richard A.
Published: April 2023

DOC file, 32.5KB.
Supplementary Table 7 from Gene Expression Profile in Response to Doxorubicin–Rapamycin Combined Treatment of HER-2–Overexpressing Human Mammary Epithelial Cell Lines
Authors: Trapé Adriana Priscila , Katayama Maria Lucia Hirata , Roela Rosimeire Aparecida , Brentani Helena , Ravacci Graziela Rosa , de Araujo Lima Leandro , Brentani Maria Mitzi
Published: April 2023

PDF file - 57K
Supplementary Table 5 from Gene Expression Profile in Response to Doxorubicin–Rapamycin Combined Treatment of HER-2–Overexpressing Human Mammary Epithelial Cell Lines
Authors: Trapé Adriana Priscila , Katayama Maria Lucia Hirata , Roela Rosimeire Aparecida , Brentani Helena , Ravacci Graziela Rosa , de Araujo Lima Leandro , Brentani Maria Mitzi
Published: April 2023

PDF file - 63K
Supplementary Methods, Table 1, and Figure Legends from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
Authors: Brachmann Saskia M. , Kleylein-Sohn Julia , Gaulis Swann , Kauffmann Audrey , Blommers Marcel J.J. , Kazic-Legueux Malika , Laborde Laurent , Hattenberger Marc , Stauffer Fabian , Vaxelaire Juliane , Romanet Vincent , Henry Chrystèle , Murakami Masato , Guthy Daniel Alexander , Sterker Dario , Bergling Sebastian , Wilson Christopher , Brümmendorf Thomas , Fritsch Christine , Garcia-Echeverria Carlos , Sellers William R. , Hofmann Francesco , Maira Sauveur-Michel
Published: April 2023

PDF file, 131KB.
Supplementary Methods, Figures 1-7 from An Anti-Wnt5a Antibody Suppresses Metastasis of Gastric Cancer Cells In Vivo by Inhibiting Receptor-Mediated Endocytosis
Authors: Hanaki Hideaki , Yamamoto Hideki , Sakane Hiroshi , Matsumoto Shinji , Ohdan Hideki , Sato Akira , Kikuchi Akira
Published: April 2023

PDF file - 551K
Supplementary Figure 2B from Antitumor Effect of SIRT1 Inhibition in Human HCC Tumor Models In Vitro and In Vivo
Authors: Portmann Simone , Fahrner René , Lechleiter Antje , Keogh Adrian , Overney Sarah , Laemmle Alexander , Mikami Kei , Montani Matteo , Tschan Mario P. , Candinas Daniel , Stroka Deborah
Published: April 2023

PDF file - 58K, SIRT1 knockdown in Hep3B and HuH7 cells
Supplementary Methods, Tables 1-4, Figures 1-4 from SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo
Authors: Pan Youli , Xu Yong , Feng Shan , Luo Shidong , Zheng Renlin , Yang Jiao , Wang Lijiao , Zhong Lei , Yang Han-Yu , Wang Bing-Lin , Yu Yang , Liu Jingjing , Cao Zhixing , Wang Xiaoyan , Ji Pan , Wang Zerong , Chen Xin , Zhang Shuang , Wei Yu-Quan , Yang Sheng-Yong
Published: April 2023

PDF file - 466K
Supplementary Figure 4 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Authors: Williams Terence M. , Flecha Athena R. , Keller Paul , Ram Ashwin , Karnak David , Galbán Stefanie , Galbán Craig J. , Ross Brian D. , Lawrence Theodore S. , Rehemtulla Alnawaz , Sebolt-Leopold Judith
Published: April 2023

PDF file, 332KB, Immunoblotting for cleaved PARP 24 hours after radiation treatment, PD0325901, and API-2 treatment to detect activation of apoptotic pathways.
Supplementary Figure 2 from ATP Citrate Lyase Knockdown Induces Growth Arrest and Apoptosis through Different Cell- and Environment-Dependent Mechanisms
Authors: Zaidi Nousheen , Royaux Ines , Swinnen Johannes V. , Smans Karine
Published: April 2023

PDF file, 56KB, Reduction in protein expression of ACLY by IPTG-inducible shRNA targeting ACLY in HOP62 and HepG2 cells.
Supplementary Figure Legend from Glycolytic Inhibition Alters Anaplastic Thyroid Carcinoma Tumor Metabolism and Improves Response to Conventional Chemotherapy and Radiation
Authors: Sandulache Vlad C. , Skinner Heath D. , Wang Yuan , Chen Yunyun , Dodge Cristina T. , Ow Thomas J. , Bankson James A. , Myers Jeffrey N. , Lai Stephen Y.
Published: April 2023

PDF file, 55KB.
Supplementary Table 1 from A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface
Authors: Tang Zhewei , Feng Mingqian , Gao Wei , Phung Yen , Chen Weizao , Chaudhary Amit , Croix Brad St. , Qian Min , Dimitrov Dimiter S. , Ho Mitchell
Published: April 2023

PDF file - 51K, Phage panning.
Supplementary Figure 3 from A Role for Homologous Recombination and Abnormal Cell-Cycle Progression in Radioresistance of Glioma-Initiating Cells
Authors: Lim Yi Chieh , Roberts Tara L. , Day Bryan W. , Harding Angus , Kozlov Sergei , Kijas Amanda W. , Ensbey Kathleen S. , Walker David G. , Lavin Martin F.
Published: April 2023

PDF file, 416K, The effect of IR on neurosphere size and apoptosis.
Supplementary Table 1 from Synthetic Lethal Screening with Small-Molecule Inhibitors Provides a Pathway to Rational Combination Therapies for Melanoma
Authors: Roller Devin G. , Axelrod Mark , Capaldo Brian J. , Jensen Karin , Mackey Aaron , Weber Michael J. , Gioeli Daniel
Published: April 2023

XLSX file, 10K, Major known genotypes of melanoma cell lines.
Supplementary Figure 3 from Breast Cancer–Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown
Authors: Previdi Sara , Abbadessa Giovanni , Dalò Francesca , France Dennis S. , Broggini Massimo
Published: April 2023

PDF file - 32K
Supplementary Figure 3 from Sensitization of TRAIL-Induced Cell Death by 20(S)-Ginsenoside Rg3 via CHOP-Mediated DR5 Upregulation in Human Hepatocellular Carcinoma Cells
Authors: Lee Ju-Yeon , Jung Kyung Hee , Morgan Michael J. , Kang Yi-Rae , Lee Hee-Seung , Koo Gi-Bang , Hong Soon-Sun , Kwon Sung Won , Kim You-Sun
Published: April 2023

PDF file - 225K, Pretreatment, but not postreatment of cells with Rg3 has a sensitization effect in TRAIL- induced cell death
Supplementary Table 6 from A Systems Biology Approach Identifies SART1 as a Novel Determinant of Both 5-Fluorouracil and SN38 Drug Resistance in Colorectal Cancer
Authors: Allen Wendy L. , Stevenson Leanne , Coyle Vicky M. , Jithesh Puthen V. , Proutski Irina , Carson Gail , Gordon Michael A. , Lenz Heinz-Josef D. , Van Schaeybroeck Sandra , Longley Daniel B. , Johnston Patrick G.
Published: April 2023

PDF file - 64K, unsupervised top 10 positive and negative correlated genes - SN38 inducible.
Supplementary Figure 2 from Targeting the Glyoxalase Pathway Enhances TRAIL Efficacy in Cancer Cells by Downregulating the Expression of Antiapoptotic Molecules
Authors: Taniguchi Hiroya , Horinaka Mano , Yoshida Tatsushi , Yano Kimihiro , Goda Ahmed E. , Yasuda Shusuke , Wakada Miki , Sakai Toshiyuki
Published: April 2023

PDF file, 77K, ROS is not involved in the apoptosis induced by methylglyoxal with TRAIL.
Supplementary Figure 3 from MLN0905, a Small-Molecule PLK1 Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
Authors: Shi Judy Quiju , Lasky Kerri , Shinde Vaishali , Stringer Bradley , Qian Mark G. , Liao Debra , Liu Ray , Driscoll Denise , Nestor Michelle Tighe , Amidon Benjamin S. , Rao Youlan , Duffey Matt O. , Manfredi Mark G. , Vos Tricia J. , Amore Natalie D' , Hyer Marc L.
Published: April 2023

PDF file, 45KB, MLN0905 yields significant anti-tumor responses in mice bearing subcutaneous OCI LY-19-Luc tumors.
Supplementary Figure 2 from Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling
Authors: Thurn K. Ted , Thomas Scott , Raha Paromita , Qureshi Ian , Munster Pamela N.
Published: April 2023

PDF file, 254K, Vorinostat induces DNA double strand breaks.
Supplementary Table 1 from TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens
Authors: Hikichi Yuichi , Honda Kohei , Hikami Kouki , Miyashita Hitoshi , Kaieda Isao , Murai Saomi , Uchiyama Noriko , Hasegawa Maki , Kawamoto Tomohiro , Sato Takashi , Ichikawa Takashi , Cao Sheldon , Nie Zhe , Zhang Lilly , Yang Johnny , Kuida Keisuke , Kupperman Erik
Published: April 2023

PDF file - 61K
Supplementary Figure 1 from Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells
Authors: Chang De-Kuan , Sui Jianhua , Geng Shusheng , Muvaffak Asli , Bai Mei , Fuhlbrigge Robert C. , Lo Agnes , Yammanuru Anuradha , Hubbard Luke , Sheehan Jared , Campbell James J. , Zhu Quan , Kupper Thomas S. , Marasco Wayne A.
Published: April 2023

PDF file, 209K, Epitope mapping of mAb1567.
Supplementary Figure Legends from Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
Authors: Fiskus Warren , Verstovsek Srdan , Manshouri Taghi , Smith Jacqueline E. , Peth Karissa , Abhyankar Sunil , McGuirk Joseph , Bhalla Kapil N.
Published: April 2023

Legends for Supplementary Figures 1-5.
Supplementary Figure 3 from Evading Pgp Activity in Drug-Resistant Cancer Cells: A Structural and Functional Study of Antitubulin Furan Metotica Compounds
Authors: Nguyen Tam Luong , Cera Maria Rosaria , Pinto Andrea , Lo Presti Leonardo , Hamel Ernest , Conti Paola , Gussio Rick , De Wulf Peter
Published: April 2023

PDF file, 223KB, Growth inhibition profiles of the NCI60 tumor cell lines by S-A8.
Supplementary Figure 2 from Evading Pgp Activity in Drug-Resistant Cancer Cells: A Structural and Functional Study of Antitubulin Furan Metotica Compounds
Authors: Nguyen Tam Luong , Cera Maria Rosaria , Pinto Andrea , Lo Presti Leonardo , Hamel Ernest , Conti Paola , Gussio Rick , De Wulf Peter
Published: April 2023

PDF file, 229KB, Growth inhibition profiles of the NCI60 tumor cell lines by R-A8.
Supplementary Figure Legends from Targeting FoxM1 Effectively Retards p53-Null Lymphoma and Sarcoma
Authors: Wang Zebin , Zheng Yu , Park Hyun Jung , Li Jing , Carr Janai R. , Chen Yi-ju , Kiefer Megan M. , Kopanja Dragana , Bagchi Srilata , Tyner Angela L. , Raychaudhuri Pradip
Published: April 2023

PDF file - 70 KB
Supplementary Figures 1 - 6 from ATP Citrate Lyase Mediates Resistance of Colorectal Cancer Cells to SN38
Authors: Zhou Yunfei , Bollu Lakshmi Reddy , Tozzi Federico , Ye Xiangcang , Bhattacharya Rajat , Gao Guang , Dupre Elizabeth , Xia Ling , Lu Jia , Fan Fan , Bellister Seth , Ellis Lee M. , Weihua Zhang
Published: April 2023

PDF file - 840K, Suppl. Figure 1. Conversion of CPT-11 (irinotican) to SN-38 by carboxylesterase; Suppl. Figure 2. Western blot analysis of the basal expression status of ACLy in a panel of colon cancer cell (CRC) lines; Suppl. Figure 3. Overexpression of fatty acid synthase (FASN) inhibited ACLy inhibition induced sensitization of HT29 cells to SN38; Suppl. Figure 4. Increased lipid droplets in HT29 cells that are resistant to SN38 (HT29-SNR) or oxaliplatin (HT29-OxR); Suppl. Figure 5. HT29-SNR cells exhibited enhanced de novo lipogenesis; Suppl. Figure 6. Co-targeting ACLy and AKT re-sensitized HT29-SNR cells to SN38.
Supplementary Figure 3 from Mechanism of Drug Efficacy Within the EGF Receptor Revealed by Microsecond Molecular Dynamics Simulation
Authors: Wan Shunzhou , Wright David W. , Coveney Peter V.
Published: April 2023

PDF file - 64K, Backbone root-mean-square fluctuations (RMSF) from the average structures of wild-type and L858R mutant EGFRs
Supplementary Table S1 from Novel Treatment for Mantle Cell Lymphoma Including Therapy-Resistant Tumor by NF-κB and mTOR Dual-Targeting Approach
Authors: Chaturvedi Nagendra K. , Rajule Rajkumar N. , Shukla Ashima , Radhakrishnan Prakash , Todd Gordon L. , Natarajan Amarnath , Vose Julie M. , Joshi Shantaram S.
Published: April 2023

PDF file - 52 KB, IC50 of 13-197 in different MCL cell lines
Supplementary Figures S1-S3 from Novel Treatment for Mantle Cell Lymphoma Including Therapy-Resistant Tumor by NF-κB and mTOR Dual-Targeting Approach
Authors: Chaturvedi Nagendra K. , Rajule Rajkumar N. , Shukla Ashima , Radhakrishnan Prakash , Todd Gordon L. , Natarajan Amarnath , Vose Julie M. , Joshi Shantaram S.
Published: April 2023

PDF file - 633 KB, Figure S1: Effect of 13-197 on the viability of normal B (nB) cells. Figure S2: Constitutive activation of NF-kB and mTOR pathway in different MCL cells. Figure S3: Effect of 13-197 on the activation of mTOR pathway molecules.
Supplementary Figure 1 from Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer
Authors: Li Rui , Hu Zhongliang , Sun Shi-Yong , Chen Zhuo G. , Owonikoko Taofeek K. , Sica Gabriel L. , Ramalingam Suresh S. , Curran Walter J. , Khuri Fadlo R. , Deng Xingming
Published: April 2023

PDF file, 171K, Inhibition of EGFR by erlotinib (Erlo) results in STAT3 phosphorylation at Tyr 705 and increased Bcl2/Bcl-XL in human lung cancer H1650 and H1975 cells.
Supplementary Figure 2 from SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis
Authors: Masuda Takeshi , Hattori Noboru , Senoo Tadashi , Akita Shin , Ishikawa Nobuhisa , Fujitaka Kazunori , Haruta Yoshinori , Murai Hiroshi , Kohno Nobuoki
Published: April 2023

PDF - 158KB, PAI-1 expression in subcutaneous tumors of LLC or B16 cells excised from PAI-1-/- mice
Supplementary Figure 4 from Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: A Light-Activated Antitumor Platinum Complex That Kills Human Cancer Cells by an Apoptosis-Independent Mechanism
Authors: Westendorf Aron F. , Woods Julie A. , Korpis Katharina , Farrer Nicola J. , Salassa Luca , Robinson Kim , Appleyard Virginia , Murray Karen , Grünert Renate , Thompson Alastair M. , Sadler Peter J. , Bednarski Patrick J.
Published: April 2023

PDF file, 121KB, 14N {1H} NMR spectra monitoring the irradiation of 3 in buffered solution.
Supplementary Figure 5 from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
Authors: Kim Sun Mi , Yun Mi Ran , Hong Yun Kyoung , Solca Flavio , Kim Joo-Hang , Kim Hyun-Jung , Cho Byoung Chul
Published: April 2023

PDF file, 1410K, Downregulation of Mcl-1 by the combined treatment of 2DG and afatinib is occurred through the blockade of cellular translation.
Supplementary Figure 2 from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
Authors: Kim Sun Mi , Yun Mi Ran , Hong Yun Kyoung , Solca Flavio , Kim Joo-Hang , Kim Hyun-Jung , Cho Byoung Chul
Published: April 2023

PDF file, 2910K, AMPK/mTOR/Mcl-1 signaling pathway mediates growth inhibition by combined treatment with 2DG and afatinib.
Supplementary Table 1 from Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes
Authors: Allen Joshua E. , Ferrini Roger , Dicker David T. , Batzer Glenda , Chen Elise , Oltean Daniela I. , Lin Bing , Renshaw Mark W. , Kretz-Rommel Anke , El-Deiry Wafik S.
Published: April 2023

PDF file, 30K, Combining DR4 Atrimer� complexes with TRAIL. Sub-G1 content in HCT116 cells treated with 1G2 (50 ng/mL) or TRAIL (25 ng/mL) for 24 hours (n=2).
Supplementary Figure Legends 1-5 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Authors: Davies Barry R. , Greenwood Hannah , Dudley Phillippa , Crafter Claire , Yu De-Hua , Zhang Jingchuan , Li Jing , Gao Beirong , Ji Qunsheng , Maynard Juliana , Ricketts Sally-Ann , Cross Darren , Cosulich Sabina , Chresta Christine C. , Page Ken , Yates James , Lane Clare , Watson Rebecca , Luke Richard , Ogilvie Donald , Pass Martin
Published: April 2023

PDF file - 73K
Supplementary Figure 6 from Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes
Authors: Allen Joshua E. , Ferrini Roger , Dicker David T. , Batzer Glenda , Chen Elise , Oltean Daniela I. , Lin Bing , Renshaw Mark W. , Kretz-Rommel Anke , El-Deiry Wafik S.
Published: April 2023

PDF file, 84K, Excess soluble DR4, but not DR5, blocks the cytotoxic effect of agonist DR4 Atrimer � complexes. Atrimer� complex 1C9 was pre-incubated with or without soluble DR4-Fc or DR5-Fc for 1 hour before addition to Colo205 cells. Cell viability was measured at 48 hours using the ViaLight Plus kit.
Supplementary Figure 5 from Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes
Authors: Allen Joshua E. , Ferrini Roger , Dicker David T. , Batzer Glenda , Chen Elise , Oltean Daniela I. , Lin Bing , Renshaw Mark W. , Kretz-Rommel Anke , El-Deiry Wafik S.
Published: April 2023

PDF file, 55K, Surface DR4 knockdown. Surface DR4 by flow cytometry in HCT116 cells transfected with a scramble control or DR4 siRNA.
Supplementary Figure 3 from Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes
Authors: Allen Joshua E. , Ferrini Roger , Dicker David T. , Batzer Glenda , Chen Elise , Oltean Daniela I. , Lin Bing , Renshaw Mark W. , Kretz-Rommel Anke , El-Deiry Wafik S.
Published: April 2023

PDF file, 131K,Atrimer� complexes are not cytotoxic to TRAIL-resistant tumor cell lines. Cell viability with candidate DR4 Atrimer� complex treatment for 48 hours in (A) HepG2 and (B) MDA-MB-231 cell lines (n=2).
Supplementary Figure 8 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Authors: Maira Sauveur-Michel , Pecchi Sabina , Huang Alan , Burger Matthew , Knapp Mark , Sterker Dario , Schnell Christian , Guthy Daniel , Nagel Tobi , Wiesmann Marion , Brachmann Saskia , Fritsch Christine , Dorsch Marion , Chène Patrick , Shoemaker Kevin , De Pover Alain , Menezes Daniel , Martiny-Baron Georg , Fabbro Doriano , Wilson Christopher J. , Schlegel Robert , Hofmann Francesco , García-Echeverría Carlos , Sellers William R. , Voliva Charles F.
Published: April 2023

PDF file - 727K
Supplementary Table 2 from Targeting Subcellular Localization through the Polo-Box Domain: Non-ATP Competitive Inhibitors Recapitulate a PLK1 Phenotype
Authors: McInnes Campbell , Estes Kara , Baxter Merissa , Yang Zhengguan , Farag Doaa Boshra , Johnston Paul , Lazo John S. , Wang Jianjun , Wyatt Michael D.
Published: April 2023

PDF file - 39K, R group definitions
Supplementary Figure Legend from First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer
Authors: Brizuela Leyre , Ader Isabelle , Mazerolles Catherine , Bocquet Magalie , Malavaud Bernard , Cuvillier Olivier
Published: April 2023

PDF file, 75K.
Supplementary Table 1 from Simultaneous Targeting of COX-2 and AKT Using Selenocoxib-1-GSH to Inhibit Melanoma
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Desai Dhimant , Amin Shantu , Robertson Gavin P.
Published: April 2023

PDF file - 60K, Selenocoxib-1-GSH is not toxic to mice
Supplementary Figure Legend from Inhibition of Monocarboxylate Transporter 2 Induces Senescence-Associated Mitochondrial Dysfunction and Suppresses Progression of Colorectal Malignancies In Vivo
Authors: Lee Inkyoung , Lee Sook-Ja , Kang Won Ki , Park Chaehwa
Published: April 2023

PDF file, 70K.
Supplementary Table S1 from A Second-Generation 2-Methoxyestradiol Prodrug Is Effective against Barrett's Adenocarcinoma in a Mouse Xenograft Model
Authors: Kambhampati Suman , Rajewski Roger A. , Tanol Mehmet , Haque Inamul , Das Amlan , Banerjee Snigdha , Jha Saheli , Burns Douglas , Borrego-Diaz Emma , Van Veldhuizen Peter J. , Banerjee Sushanta K.
Published: April 2023

PDF file - 59KB, Rat 2-ME2 and 2-ME2-PD1 dosing summary
Supplementary Figure Legend from Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
Authors: Acquaviva Jaime , Smith Donald L. , Sang Jim , Friedland Julie C. , He Suqin , Sequeira Manuel , Zhang Chaohua , Wada Yumiko , Proia David A.
Published: April 2023

PDF file - 64K
Supplementary Table 6 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
Authors: Chen Min , Shabashvili Daniel , Nawab Akbar , Yang Sherry X. , Dyer Lisa M. , Brown Kevin D. , Hollingshead Melinda , Hunter Kent W. , Kaye Frederic J. , Hochwald Steven N. , Marquez Victor E. , Steeg Patricia , Zajac-Kaye Maria
Published: April 2023

PDF file - 335K, Differentially down-regulated genes (>1.5-fold differences; P < 0.05) from mammary tumors of the PyMT transgenic mice exposed to zebularine for 48 days.
Supplementary Table 4 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
Authors: Chen Min , Shabashvili Daniel , Nawab Akbar , Yang Sherry X. , Dyer Lisa M. , Brown Kevin D. , Hollingshead Melinda , Hunter Kent W. , Kaye Frederic J. , Hochwald Steven N. , Marquez Victor E. , Steeg Patricia , Zajac-Kaye Maria
Published: April 2023

PDF file - 310K, Differentially down-regulated genes (>1.5-fold differences; P < 0.05) from mammary tumors of the PyMT transgenic mice exposed to zebularine for 23 days.
Supplementary Table 1 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
Authors: Chen Min , Shabashvili Daniel , Nawab Akbar , Yang Sherry X. , Dyer Lisa M. , Brown Kevin D. , Hollingshead Melinda , Hunter Kent W. , Kaye Frederic J. , Hochwald Steven N. , Marquez Victor E. , Steeg Patricia , Zajac-Kaye Maria
Published: April 2023

PDF file - 401K, Differentially up-regulated genes (>1.5-fold differences; P < 0.05) from mammary tumors of the PyMT transgenic mice exposed to zebularine for 13 days.
Supplementary Table 1 from Redirecting Apoptosis to Aponecrosis Induces Selective Cytotoxicity to Pancreatic Cancer Cells through Increased ROS, Decline in ATP Levels, and VDAC
Authors: Dinnen Richard D. , Mao Yuehua , Qiu Wanglong , Cassai Nicholas , Slavkovich Vesna N. , Nichols Gwen , Su Gloria H. , Brandt-Rauf Paul , Fine Robert L.
Published: April 2023

PDF - 53KB, Supplementary Table 1: Tumor size in mm3, SD, SE and N for Control and AAA-treated mice. Two tumors per animal, 21 animals per group at week 0. Data summarized in graphical form in Fig. 6A.
Supplementary Methods from Redirecting Apoptosis to Aponecrosis Induces Selective Cytotoxicity to Pancreatic Cancer Cells through Increased ROS, Decline in ATP Levels, and VDAC
Authors: Dinnen Richard D. , Mao Yuehua , Qiu Wanglong , Cassai Nicholas , Slavkovich Vesna N. , Nichols Gwen , Su Gloria H. , Brandt-Rauf Paul , Fine Robert L.
Published: April 2023

PDF - 44KB, ROS terms.